Publication alert – A review of non-nucleotide biomarker discovery protocols from body fluids in breast cancer diagnosis

June 16th, 2023

Breast cancer has now become the most commonly diagnosed cancer, accounting for one in eight cancer diagnoses worldwide.

Various studies and techniques have been designed to discover biomarkers in biofluids, such as saliva, for non-invasive early detection and prognosis of cancers. Despite the importance of this, the reported markers are often inconsistent and irreproducible across different studies and cohorts.

In this article, the authors reviewed the ongoing trend of non-nucleotide biomarkers, including lipidomics, proteomics and metabolomics, derived from body fluids, with a focus on breast cancer.  The inconstancies in the biomarker discovery pipelines across pre-analytical, analytical, and post-analytical phases, are reviewed. This covers the diversity of approaches from sample processing to predictive modelling and validation.

Manuscript co-author – Dr Azadeh Safarchi

Collaborative partners

School of Biotechnology and Biomolecular Sciences, University of New South
Wales (UNSW Sydney), Sydney, NSW 2052, Australia

BCAL Diagnostics Ltd., Suite 506, 50 Clarence St, Sydney, NSW 2000,

BCAL Dx, The University of Sydney, Sydney Knowledge Hub, Merewether
Building, Sydney, NSW 2006, Australia

UNSW Data Science Hub (uDASH), University of New South Wales (UNSW Sydney),
Sydney, NSW 2052, Australia Pty Ltd., Sydney, NSW 2035, Australia

View the full manuscript –

See more of Azadeh’s and the human gut health team’s research:

Human gut microbiome – Microbiomes (